Want to see IN:JHS full AI Analyst Report?
Top Page
JHS Svendgaard Laboratories Limited
(JHS)
Select Model
Select Model
Rating:44Neutral
Price Target:
₹7.50
▲(1.21% Upside)
Action:Reiterated
Date:06/09/26
The score is held down primarily by weak financial performance—ongoing losses, margin pressure, and continued cash burn—despite a low-leverage balance sheet. Technicals also remain bearish with price below key moving averages and negative MACD, while valuation is difficult to assess due to negative earnings and no dividend data.
Positive Factors
Low Leverage / Balance Sheet Strength
Low leverage and a stable asset/equity base give the company durable solvency flexibility, reducing default and refinancing risk. Over 2–6 months this balance-sheet strength supports continued operations, potential opportunistic investment, and resilience against cyclical revenue swings.
Negative Factors
Ongoing Net Losses
Persistent operating losses erode retained earnings and limit internal funding for growth or product investment. Over months, continued negative margins constrain strategic flexibility, elevate dependence on cash reserves or financing, and make it harder to convert balance-sheet strength into shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Balance Sheet Strength
Low leverage and a stable asset/equity base give the company durable solvency flexibility, reducing default and refinancing risk. Over 2–6 months this balance-sheet strength supports continued operations, potential opportunistic investment, and resilience against cyclical revenue swings.
Read all positive factors
JHS Svendgaard Laboratories Limited (JHS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹694.88M
Dividend YieldN/A
Average Volume (3M)16.78K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth19.41%
EPS Growth89.58%
CountryIN
Employees250
SectorGeneral
Sector StrengthN/A
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.23
Shares Outstanding87,405,770
10 Day Avg. Volume16,348
30 Day Avg. Volume16,781
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)0.33
Price to Sales (P/S)0.56
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
JHS Svendgaard Laboratories Limited Business Overview & Revenue Model
Company Description
JHS Svendgaard Laboratories Limited, along with its associated companies, specializes in the manufacturing and sale of a diverse array of oral and dental hygiene products, catering to both adults and children throughout India. Their extensive prod...
How the Company Makes Money
JHS primarily makes money by manufacturing and supplying finished consumer products (notably oral care products such as toothpaste) to customers and receiving revenue from the sale of those goods. A key revenue stream is typically contract manufac...
JHS Svendgaard Laboratories Limited Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.02B | 919.97M | 698.06M | 840.82M | 854.91M |
| Gross Profit | 177.22M | 309.55M | 203.55M | 165.45M | 201.68M |
| EBITDA | 60.64M | -39.92M | 33.78M | -163.82M | 85.45M |
| Net Income | -19.22M | -197.44M | -40.58M | -175.17M | -40.52M |
Balance Sheet | |||||
| Total Assets | 2.15B | 2.01B | 1.97B | 2.28B | 2.22B |
| Cash, Cash Equivalents and Short-Term Investments | 191.00M | 200.16M | 94.56M | 386.51M | 80.19M |
| Total Debt | 148.51M | 64.58M | 51.29M | 155.09M | 61.82M |
| Total Liabilities | 405.49M | 284.41M | 271.70M | 543.87M | 269.46M |
| Stockholders Equity | 1.75B | 1.73B | 1.70B | 1.74B | 1.86B |
Cash Flow | |||||
| Free Cash Flow | -148.91M | -157.11M | -401.17M | 89.43M | -158.75M |
| Operating Cash Flow | -20.97M | -51.78M | -85.84M | 232.86M | -91.36M |
| Investing Cash Flow | -130.38M | -220.18M | -217.34M | 96.77M | -46.97M |
| Financing Cash Flow | 121.43M | 232.97M | 21.74M | -9.00M | -16.72M |
JHS Svendgaard Laboratories Limited Technical Analysis
Positive
7.41
Price Trends
7.79
Positive
8.16
Positive
9.43
Negative
Market Momentum
0.14
Negative
74.40
Negative
54.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Positive. The current price of 7.41 is below the 20-day moving average (MA) of 7.61, below the 50-day MA of 7.79, and below the 200-day MA of 9.43, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 74.40 is Negative, neither overbought nor oversold. The STOCH value of 54.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JHS.
JHS Svendgaard Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹546.99B | 40.52 | ― | 2.30% | 3.79% | -3.28% | |
69 Neutral | ₹179.76B | 23.88 | ― | 3.38% | 2.82% | -8.52% | |
65 Neutral | ₹734.42B | 37.11 | ― | 1.95% | 7.40% | 10.63% | |
64 Neutral | ₹155.69B | 75.98 | ― | ― | 15.72% | 174.63% | |
59 Neutral | ₹1.06T | 55.21 | ― | 1.89% | 9.22% | 3.19% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | ₹694.88M | -39.39 | ― | ― | 19.41% | 89.58% |
* General Sector Average
IN:JHS
JHS Svendgaard Laboratories Limited
8.91
-3.13
-26.00%
IN:COLPAL
Colgate-Palmolive (India) Limited
1,998.80
-126.36
-5.95%
IN:DABUR
Dabur India Limited
410.00
-84.29
-17.05%
IN:EMAMILTD
Emami Limited
396.95
-174.20
-30.50%
IN:GODREJCP
Godrej Consumer Products Limited
910.60
-271.24
-22.95%
IN:HONASA
Honasa Consumer Limited
467.90
182.65
64.03%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.